NSE · Healthcare · Drug Manufacturers - Specialty & Generic
| Document | Date |
|---|---|
| Annual report FY2026 MEDICAMEN BIOTECH LIMITED - FY 2025-26 SUMMARY HEADLINE NUMBERS • Market Capitalisation (as of 31 March 2026): ₹302.86 crores • Revenue from Operati | 2026-09-03 |
| Quarterly results · Q1 FY27 MEDICAMEN BIOTECH LIMITED - DOCUMENT SUMMARY HEADLINE NUMBERS • Q1 FY2026-27 Net Sales (Standalone): Rs 4,385.27 crore (down from Rs 5,468.08 crore | 2026-08-14 |
| Quarterly results · Q4 FY26 MEDICAMEN BIOTECH LIMITED – COMPANY DOCUMENT SUMMARY HEADLINE NUMBERS • Financial Year Ended: March 31, 2026 • Dividend Recommended: Rs. 1.00 per Eq | 2026-05-27 |
| Quarterly results · Q3 FY26 MEDICAMEN BIOTECH LIMITED – FINANCIAL RESULTS SUMMARY Quarter and Nine Months Ended December 31, 2025 --- HEADLINE NUMBERS • Q3 FY2025-26 Standalon | 2026-02-13 |
| Quarterly results · Q2 FY26 MEDICAMEN BIOTECH LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • Net Profit (H1 FY2025-26): Rs. 384.22 lakhs (standalone), Rs. 371.48 lakhs (consoli | 2025-11-14 |
| Annual report FY2025 MEDICAMEN BIOTECH LIMITED - ANNUAL REPORT 2024-25 SUMMARY HEADLINE NUMBERS • Revenue from Operations (Standalone): ₹15,146.33 Lakhs in FY2024-25, do | 2025-09-03 |
| Quarterly results · Q1 FY26 MEDICAMEN BIOTECH LIMITED – BOARD MEETING OUTCOME SUMMARY Date: August 12, 2025 --- HEADLINE NUMBERS • Q1 FY2025-26 Financial Results: Un-audited s | 2025-08-12 |
| Quarterly results | 2025-02-11 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹1 / share ex-date Sep 19, 2025 | 2025-09-19 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Medicamen Biotech Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.